MIB-626 + Exercise for Healthy Adults
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called MIB-626, which involves taking a supplement to determine if it enhances fitness when combined with exercise. The study targets healthy, highly active individuals who regularly engage in intense exercise. Participants will receive either MIB-626 or a placebo (a pill with no active ingredients) alongside their usual workout routine or a specific high-intensity exercise plan. It suits those already physically fit and accustomed to vigorous exercise routines, such as running or weight training. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, allowing participants to contribute to the development of potentially beneficial fitness enhancements.
Do I have to stop taking my current medications for the trial?
You may need to stop taking certain supplements, especially those containing niacin or its related compounds, at least 2 weeks before starting the trial. Herbal supplements and performance-enhancing substances are also prohibited. If you're taking any of these, you'll need to stop before participating.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that MIB-626, which includes a compound called NMN, is generally safe for people. Studies indicate that taking up to 1250 mg of NMN daily for 4 weeks does not cause major side effects, and participants tolerated it well. Another study found that MIB-626 increased NAD+ levels without causing inflammation or kidney problems.
High-intensity interval training (HIIT) is also considered safe for the exercise component. Even older adults with heart conditions have safely participated in supervised HIIT programs. HIIT helps improve fitness and overall health.
In summary, previous research has demonstrated the safety of both the MIB-626 treatment and the exercise routine used in the trial.12345Why are researchers excited about this trial's treatments?
Researchers are excited about MIB-626 because it uses nicotinamide mononucleotide (NMN), a compound that may stimulate cellular energy production by boosting NAD+ levels. Unlike traditional exercise alone, MIB-626 might enhance the body's natural ability to repair and maintain itself, potentially leading to improved physical performance and recovery. This treatment is unique because it combines the benefits of exercise with a novel biochemical approach, possibly offering quicker and more effective results than exercise alone.
What evidence suggests that this trial's treatments could be effective for healthy adults?
Research has shown that MIB-626, which includes NMN (a compound aiding energy and cell repair), can increase NAD levels in the blood. Studies have found that NMN is safe and can reduce tiredness and improve leg strength in the afternoon. It might also help with aging-related issues, such as cellular stress and DNA damage.
In this trial, some participants will receive MIB-626 alongside their usual physical activity, while others will combine MIB-626 with a standardized, progressive, high-intensity, multidimensional exercise program. High-intensity exercise has been proven to improve heart and lung fitness, reduce body fat, and boost overall physical performance. These findings suggest that MIB-626 and high-intensity exercise together could enhance physical fitness and health.16789Who Is on the Research Team?
Shalender Bhasin, MD
Principal Investigator
Brigham and Women's Hospital
Are You a Good Fit for This Trial?
This trial is for healthy, fit individuals aged 19-40 who regularly engage in high-intensity exercise and meet specific fitness criteria (VO2max of at least 40 mL/kg/min). Participants must have a BMI between 18.5 and 32, be willing to undergo intensive training or maintain usual activity based on group assignment, and not plan to become pregnant. Exclusions include certain medical conditions, use of performance-enhancing drugs or prohibited medications, competing athletes, and contraindications to MRI/MRS.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either 1000 mg NMN or placebo twice daily for 10 weeks, with or without a high-intensity exercise program
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- High-Intensity Multi-Dimensional Exercise Training Program
- MIB-626
- Placebo
- Usual Physical Activity
Find a Clinic Near You
Who Is Running the Clinical Trial?
Metro International Biotech, LLC
Lead Sponsor